Highland Capital Management 13F: New $3.1M Stake in GILD
Key Points
- Highland Capital Management's new stake in Gilead Sciences represents about 0.37% of its total reported value of $833.1 million.
- Highland Capital Management held 20,892 $GILD shares at quarter end, all of it a new position.
- As of October 27, 2026, Gilead's shares traded at $156.04, slightly below the $158.69 closing price on October 26, marking a 1.7% decrease since then.
- Gilead Sciences has a market cap of approximately $196.8 billion and is currently in a sector with a consensus analyst rating of 'buy' and a mean price target of $160.19.
Get Gilead Sciences text alerts
We text you when insiders, Congress, analysts or big funds move on $GILD.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Gilead Sciences, Inc. alert may contain errors. Disclosures
Highland Capital Management took a new position of 20,892 shares in Gilead Sciences, Inc. (GILD), valued at $3,113,953, in a filing on October 26, 2026. This information comes from the fund's latest Form 13F filing with the SEC.
In this filing, Highland reported a total value of $833,056,275 for its portfolio, ranking 28th among 415 positions. The new stake in Gilead accounts for about 0.37% of the fund's total reported value.
GILD
Gilead Sciences, Inc.
Other Institutional Activity in Gilead Sciences
Several other funds have also adjusted their positions in Gilead. Royal Fund Management added 21,288 shares, bringing its total to 23,861 shares worth about $3,556,585. CWA Asset Management Group increased its stake by 15,240 shares, for a total of 78,639 shares valued at approximately $11,721,086. Meanwhile, UniSuper Management reduced its position by 122,968 shares, leaving it with 228,720 shares worth around $34,090,716.
Gilead Sciences, Inc. Stock Holds Steady
As of October 27, 2026, Gilead's shares traded at $156.04, which is slightly below the $158.69 closing price on October 26. This price is about 1.7% lower than the previous close but remains above both the 50-day and 200-day moving averages, which are currently at $149.25 and $139.06, respectively. The stock is also trading 36.9% above its 52-week low of $114.02.
Recent Earnings
Gilead Sciences reported trailing twelve-month revenue of approximately $30.5 billion, reflecting a year-over-year growth of 10.2%. The next earnings report is scheduled for October 29, 2026.
Dividend
Gilead pays an annual dividend rate of $3.28 per share, resulting in a yield of about 2.07%. The dividend payout ratio stands at 43.5%.
Insider Buying and Selling at Gilead Sciences, Inc.
Several insiders have sold shares of Gilead recently. On August 26, 2026, Director Anthony Welters sold 18,000 shares, valued at approximately $2,675,220. CEO Daniel Patrick O'Day sold 15,000 shares on September 1, 2026, worth about $2,229,592. Additionally, Officer Johanna Mercier sold 3,000 shares on September 15, 2026, valued at $432,646, and CFO Andrew D. Dickinson sold 3,000 shares on the same day for approximately $435,870.
Analysts Set New Price Targets
On October 20, 2026, B of A Securities maintained a 'buy' rating for Gilead with a price target of $172.00. Truist Securities also maintained a 'buy' rating with a target of $158.00, while JP Morgan kept its 'overweight' rating with a target of $170.00. The consensus recommendation from analysts is 'buy,' with a mean price target of $160.19.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines to address unmet medical needs. The company is known for its treatments for HIV-1 infection and has a strong position in the healthcare sector.
Bottom Line
Investors should keep an eye on Gilead's upcoming earnings report on October 29, 2026, which may provide further insight into the company's performance. Highland Capital Management's recent filing reflects a strategic move into Gilead, adding to the ongoing interest in the biotechnology sector.
Related Filing Alerts
Source: Highland Capital Management's 13F filing on $GILD (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts